The main goal of the project is to deliver an innovative and effective cancer drug to patients. We will also develop a companion diagnostic tool to allow the early identification of patients that will benefit from this novel treatment. The ultimate goal is to reduce the burden of EU healthcare providing more efficacious treatment as a stand-alone agent or in combination with standard of care drugs.
The first sub-objective of the project is to focus the study of the efficacy of compounds that have shown a higher cytotoxicity in screening tests using cell line libraries in three specific tumor types: NSCLC, TNBC and malignant mesothelioma. These three tumor types, in which YAP1 alteration has been described, belong to the group of tumors with a lower survival rate at 5 years, so possible advances in limited treatment options are of vital importance for patients.
The second sub-objective of the project is the development of diagnostic tools for an optimal selection of patients eligible for therapy. To this end, efforts will be focused on obtaining genomic signatures related to a greater sensitivity or resistance to the compounds tested, and the validation of a new antibody for the detection and localization of YAP1 by IHC and / or IF. In both cases the final objective will be to obtain of a Companion Kit that allows the identification of the patients that can benefit from the therapy through the use of validated methods and guides of interpretation of the results for the analysis of the alterations of YAP.